జర్నల్ ఆఫ్ బ్లడ్ డిజార్డర్స్ & ట్రాన్స్‌ఫ్యూజన్

నైరూప్య

Marginal Zone Lymphoma Perge Progredi, Next on the Horizon

Hun Ju Lee, Madhav Desai, Liang Zhang, Qingqing Cai, Dehui Zou and Michael Wang

Marginal Zone Lymphoma (MZL) is a clonal indolent mature B-cell malignancy. MZL accounts for 10% of all Non-Hodgkin Lymphomas (NHL). The common etiologic hallmarks of MZL are chronic antigenic B-cell stimulation, which leads to increased DNA replication errors and genomic instability. Standard therapy for MZL has been watch and wait, cytotoxic chemotherapy, surgery, and/or radiation therapy based on clinical risk factors. However, novel developments of targeted therapies have brought new excitement to MZL therapeutic armamentarium. In this article, we provide an update on the novel diagnostic approaches to MZL as well as innovative molecular targets that will ultimately become the next therapeutic paradigm for patients with MZL.